Bernstein Maintains Market Perform on Intellia Therapeutics, Raises Price Target to $17
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Bernstein analyst William Pickering maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Perform and raises the price target from $13 to $17.
Bernstein analyst William Pickering maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Perform and raises the price target from $13 to $17.